Kiniksa Pharmaceuticals officer sells 194k in stock
KNSA Stock | USD 21.13 0.04 0.19% |
About 68% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
Kiniksa Pharmaceuticals officer sells 194k in stock
Read at investing.com
Kiniksa Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kiniksa Pharmaceuticals Fundamental Analysis
We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Kiniksa Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Kiniksa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiniksa Pharmaceuticals Related Equities
CHRS | Coherus BioSciences | 24.82 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
VTYX | Ventyx Biosciences | 6.12 | ||||
KRON | Kronos Bio | 4.44 | ||||
SPRO | Spero Therapeutics | 1.72 | ||||
DAWN | Day One | 1.55 | ||||
CGEM | Cullinan Oncology | 1.25 | ||||
PHAT | Phathom Pharmaceuticals | 1.24 | ||||
GPCR | Structure Therapeutics | 0.90 | ||||
REPL | Replimune | 0.23 | ||||
COGT | Cogent Biosciences | 0.22 | ||||
LRMR | Larimar Therapeutics | 0.16 | ||||
NUVL | Nuvalent | 0.56 | ||||
KURA | Kura Oncology | 2.06 | ||||
NVCT | Nuvectis Pharma | 3.02 | ||||
GOSS | Gossamer Bio | 4.11 | ||||
ACLX | Arcellx | 7.39 | ||||
BOLT | Bolt Biotherapeutics | 7.94 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |